Daniel Barber Biography and Net Worth

Dan Barber was appointed Chief Executive Officer, President and as a member of our Board on May 17, 2022, after having served as our Chief Operating Officer since May 2019. Daniel Barber joined Aquestive in July 2007 and has been involved in many different facets of the business. Prior to joining Aquestive, Mr. Barber held various positions with Quest Diagnostics in their corporate planning and international divisions. Over the last fifteen years Mr. Barber has been instrumental in the growth of Aquestive Therapeutics. In 2010, Mr. Barber had executive oversight of the company’s launch activities for Aquestive’s first two FDA approved products. In 2013, Mr. Barber helped lead the company’s effort to develop an internal pipeline of proprietary assets. Since that time, he has had executive responsibility for Aquestive’s pipeline and partnership activities. Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.

What is Daniel Barber's net worth?: The estimated net worth of Daniel Barber is at least $3.90 million as of March 10th, 2026. Barber owns 1,004,753 shares of Aquestive Therapeutics stock worth more than $3,898,442 as of March 24th. This net worth evaluation does not reflect any other investments that Barber may own. Additionally, Barber receives a salary of $1,060,000.00 as CEO at Aquestive Therapeutics. Learn More about Daniel Barber's net worth.
How old is Daniel Barber?: Barber is currently 48 years old. There are 6 older executives and 2 younger executives at Aquestive Therapeutics. Learn More on Daniel Barber's age.
What is Daniel Barber's salary?: As the CEO of Aquestive Therapeutics, Inc., Barber earns $1,060,000.00 per year. Learn More on Daniel Barber's salary.
How do I contact Daniel Barber?: The corporate mailing address for Barber and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Daniel Barber's contact information.
Has Daniel Barber been buying or selling shares of Aquestive Therapeutics?: During the last quarter, Daniel Barber has sold $753,423.09 in shares of Aquestive Therapeutics stock. Most recently, Daniel Barber sold 180,677 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $753,423.09. Following the completion of the sale, the chief executive officer now directly owns 1,004,753 shares of the company's stock, valued at $4,189,820.01. Learn More on Daniel Barber's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Daniel Barber Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2026	Sell	180,677	$4.17	$753,423.09	1,004,753
9/26/2025	Sell	91,343	$6.03	$550,798.29	923,430
9/19/2025	Sell	400	$6.00	$2,400.00	1,014,773
6/8/2022	Buy	91,743	$0.96	$88,073.28	193,702
8/27/2019	Buy	2,000	$3.99	$7,980.00
12/10/2018	Buy	1,000	$8.00	$8,000.00

Daniel Barber Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Daniel Barber Biography and Net Worth

What is Daniel Barber's net worth?

How old is Daniel Barber?

What is Daniel Barber's salary?

How do I contact Daniel Barber?

Has Daniel Barber been buying or selling shares of Aquestive Therapeutics?

Who are Aquestive Therapeutics' active insiders?

Are insiders buying or selling shares of Aquestive Therapeutics?